Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 909.40% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 72.30M.
Overvalued
The company’s latest PE is 303.30, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 9.26M shares, increasing 4.47% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 348.54K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.26.